The 5 constituents in the munKNEE Psychedelic Drug Stocks Index jumped 30.2% in November, on average, and were up a further 2.8% last week but remain down 10.1% YTD, on average.

Below is how they performed, in descending order, with pertinent news.

1. Atai Life Sciences (ATAI): up 16.3%
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read: atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
2. Compass Pathways (CMPS): up 8.2%
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Read: Compass Pathways PLC Stock Forecast
3. Incannex Healthcare (IXHL): up 5.7%
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Read: Incannex Healthcare Announces Completion of its Re-domiciliation to the United States
4. Mind Medicine (MNMD): down 2.7%
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Read: MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
5. GH Research (GHRS): down 4.2%
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Read: GH Research Stock Forecast & Price Target

Summary

The munKNEE Psychedelic Drug Stocks Index was down 14.3% in August, down another 14.2% in September and down 27.3% in October but was up 30.2% in November and was up another 2.8% last week but is still down 10.1% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, was up 2.3% and remains down 28.5% YTD.

More By This Author:

5 Largest Cannabis (Marijuana) LP Stocks Up 9% This Week
A Managed Futures ETF For Investing In Bitcoin
Silver Update: 73% Of Analysts Have Already Seen Their Targets For 2023 Surpassed